Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices (IPANEMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02838368|
Recruitment Status : Completed
First Posted : July 20, 2016
Last Update Posted : February 25, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The incidence of type II glycogen-storage disease (Pompe disease) varies depending on ethnicity and geographic region. As of 2010, nine studies have been published documenting the incidence of Pompe disease. It is most common within the African American population, with an incidence of 1 in 14,000. In the U.S. more broadly speaking, the combined incidence of all three variants of the disease is 1 in 40,000. These estimates relied on the frequencies of three mutations in the gene acid alpha-glucosidase (GAA), leading to variants of the disease. Criteria for inclusion in the studies were often non-selective; in many cases, molecular genetic screening was done at birth. With such a high prevalence of Pompe disease reported, it is expected that large university medical centers specializing in neuromuscular diseases would see a higher incidence of Pompe disease among their patients. From a comparable Italian multicenter study, it appears that Pompe disease accounts for 3% of all patients presenting with proximal weakness with or without CK elevation.
This study will measure the incidence of Pompe disease based on manifest laboratory abnormality, namely low GAA enzyme activity. Analysis of GAA enzyme activity will be determined through a blood sample of 4 mL. The study seeks to measure the epidemiology of Pompe disease by symptomatically screening all patients who present with symptoms of hitherto undiagnosed proximal weakness with or without elevation of the muscle enzyme, creatinine kinase (CK), or elevation of CK alone, at thirteen academic tertiary neuromuscular practices throughout the United States and Canada. Total recruitment is expected to be ~1,500 participants. It is anticipated that the number of incident Pompe cases in this cohort would be between 3-5%, i.e. 45-75 newly diagnosed cases of Pompe disease.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||921 participants|
|Official Title:||Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||July 2018|
|Actual Study Completion Date :||December 1, 2018|
- The true incidence of Pompe disease among patients seen at neuromuscular clinics. [ Time Frame: Two years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||8 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Age 8 years or older.
- Geographically accessible to one of the sites.
- One of these following three clinical situations: Complaint of proximal muscle weakness with or without elevation in creatinine kinase (CK); neck muscle weakness (either flexor or extensor) with or without elevation in CK; or elevation of CK in isolation.
- Capable and willing to provide informed consent or assent and follow study procedures.
- Less than 8 years of age.
- Subjects with an alternative neuromuscular diagnosis that is responsible for subject's symptoms
- Incapable or unwilling to provide informed consent and to follow research procedures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02838368
|United States, California|
|University of California, Irvine|
|Irvine, California, United States, 92868|
|Principal Investigator:||Tahseen Mozaffar, MD||University of California, Irvine|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Tahseen Mozaffar, Professor, University of California, Irvine|
|Other Study ID Numbers:||
|First Posted:||July 20, 2016 Key Record Dates|
|Last Update Posted:||February 25, 2019|
|Last Verified:||August 2018|
Glycogen Storage Disease Type II
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Lysosomal Storage Diseases